BR112012025678A2 - composição para inibição da transmissão do hiv, uso da mesma, métood para preparação da mesma e método para inibição de transmissão do hiv. - Google Patents

composição para inibição da transmissão do hiv, uso da mesma, métood para preparação da mesma e método para inibição de transmissão do hiv.

Info

Publication number
BR112012025678A2
BR112012025678A2 BR112012025678A BR112012025678A BR112012025678A2 BR 112012025678 A2 BR112012025678 A2 BR 112012025678A2 BR 112012025678 A BR112012025678 A BR 112012025678A BR 112012025678 A BR112012025678 A BR 112012025678A BR 112012025678 A2 BR112012025678 A2 BR 112012025678A2
Authority
BR
Brazil
Prior art keywords
inhibiting hiv
same
hiv transmission
composition
transmission
Prior art date
Application number
BR112012025678A
Other languages
English (en)
Portuguese (pt)
Inventor
Francis John Purcell Damian
Lichti Gorrfrield
Thomas Rawlin Grant
Keamski Marit
John Center Robert
Michael Robins-Browne Roy
Original Assignee
Immuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuron Ltd filed Critical Immuron Ltd
Publication of BR112012025678A2 publication Critical patent/BR112012025678A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012025678A 2010-04-09 2011-04-11 composição para inibição da transmissão do hiv, uso da mesma, métood para preparação da mesma e método para inibição de transmissão do hiv. BR112012025678A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32239910P 2010-04-09 2010-04-09
PCT/AU2011/000407 WO2011123900A1 (en) 2010-04-09 2011-04-11 Methods and compositions for inhibiting hiv transmission

Publications (1)

Publication Number Publication Date
BR112012025678A2 true BR112012025678A2 (pt) 2017-07-18

Family

ID=44761932

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012025678A BR112012025678A2 (pt) 2010-04-09 2011-04-11 composição para inibição da transmissão do hiv, uso da mesma, métood para preparação da mesma e método para inibição de transmissão do hiv.

Country Status (12)

Country Link
US (1) US20130022619A1 (https=)
EP (1) EP2555798B1 (https=)
JP (1) JP6026402B2 (https=)
CN (1) CN103167881B (https=)
AP (1) AP3469A (https=)
AU (2) AU2011238431B2 (https=)
BR (1) BR112012025678A2 (https=)
CA (1) CA2795853A1 (https=)
MX (1) MX343505B (https=)
RU (1) RU2594249C2 (https=)
WO (1) WO2011123900A1 (https=)
ZA (1) ZA201207790B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049524A4 (en) * 2013-09-27 2017-06-14 Duke University Hiv-1 mother-to-child transmission correlates of protection and vaccine
CN103736100B (zh) * 2013-12-25 2017-06-09 南方医科大学 预防hiv性传播的杀微生物剂酸酐修饰抗sevi多克隆抗体
JP6955487B2 (ja) * 2015-09-24 2021-10-27 アブビトロ， エルエルシー Ｈｉｖ抗体組成物および使用方法
WO2017062071A1 (en) * 2015-10-07 2017-04-13 Eca Medical Instruments Gearless washer spring torque drive
US10973679B2 (en) * 2016-02-12 2021-04-13 Adam Arreola STD detecting condom
JP2023528992A (ja) 2020-06-10 2023-07-06 ザ ユニバーシティー オブ メルボルン Ｈｉｖ－１抗体
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
JP2024521987A (ja) 2021-05-12 2024-06-05 アプライド バイオメディカル サイエンス インスティチュート ジスルフィド結合した結合ポリペプチドのスクリーニング及び発現の方法
JP7421610B1 (ja) 2022-08-18 2024-01-24 株式会社マーベラス ゲーム装置
AU2023379740A1 (en) 2022-11-16 2025-05-29 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
WO2026073047A1 (en) 2024-09-27 2026-04-02 Applied Biomedical Science Institute Methods of screening and expressing cis-display libraries of disulfide-rich polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039957A (en) * 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
DK1190101T3 (da) * 1999-06-24 2009-08-03 Univ Johns Hopkins Sammensætninger og fremgangsmåder til at forebygge transepithelial overförsel af HIV
MXPA03002643A (es) * 2000-09-28 2003-06-19 Chiron Corp Composiciones de microparticulas y metodos para producirlas.
US7939083B2 (en) * 2006-10-23 2011-05-10 Progenics Pharmaceuticals Inc. Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain
WO2009058989A1 (en) * 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as hiv-1 vaccines
WO2010096042A1 (en) * 2008-10-30 2010-08-26 Dana-Farber Cancer Institute Mimotopes of hiv env

Also Published As

Publication number Publication date
JP2013523783A (ja) 2013-06-17
AP2012006519A0 (en) 2012-10-31
RU2012142999A (ru) 2014-05-20
MX343505B (es) 2016-11-04
JP6026402B2 (ja) 2016-11-16
ZA201207790B (en) 2013-06-26
AP3469A (en) 2015-11-30
CN103167881A (zh) 2013-06-19
MX2012011574A (es) 2013-03-05
RU2594249C2 (ru) 2016-08-10
EP2555798B1 (en) 2016-06-22
EP2555798A4 (en) 2013-11-20
US20130022619A1 (en) 2013-01-24
EP2555798A1 (en) 2013-02-13
AU2017265055A1 (en) 2019-06-06
AU2011238431A1 (en) 2012-11-08
CA2795853A1 (en) 2011-10-13
CN103167881B (zh) 2017-06-16
WO2011123900A1 (en) 2011-10-13
AU2011238431B2 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
BR112012025678A2 (pt) composição para inibição da transmissão do hiv, uso da mesma, métood para preparação da mesma e método para inibição de transmissão do hiv.
MD20150064A2 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
MX383706B (es) Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
PH12015501156A1 (en) Pharmaceutical compositions
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
UA113956C2 (xx) Похідні піримідину для лікування вірусних інфекцій
MY173422A (en) Purine derivatives for the treatment of viral infections
EA201590215A1 (ru) Макроциклические пурины для лечения вирусных инфекций
EA202090547A3 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
CL2016000787A1 (es) Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih).
EA201490963A1 (ru) Новые производные гемина с антибактериальной и противовирусной активностью
UY34128A (es) Métodos, composiciones y kits para determinar el virus de la inmunodeficiencia humana (vih)?.
WO2014124092A3 (en) Lamivudine crystalline salts

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL